- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04537702
Prospective Randomized Trial of Streamlined Genetic Education and Testing for Ovarian Cancer Patients
August 25, 2021 updated by: Duke University
Prospective, Randomized Non-inferiority Trial of Streamlined Genetic Education and Testing for High-grade Epithelial Ovarian, Fallopian and Peritoneal Cancer Patients
Current guidelines recommend universal genetic testing for all patients with ovarian, fallopian and peritoneal cancer.
The purpose of this trial is to investigate the non-inferiority of streamlined genetics education and testing for this patient population when compared to the traditional model of referral to genetic counseling.
Patients will be randomized to either the streamlined or the traditional counseling arm.
Those in the streamlined group will watch a brief educational video and have the option of immediate testing; The traditional counseling arm will instead be referred for a formal genetics consultation, after which they can choose to be tested.
The primary outcome will be a patient reported outcome scale that assesses patient satisfaction with genetic counseling; patient anxiety and distress and cost effectiveness when using both strategies will also be evaluated.
The study poses minimal risk to the patients that would not be encountered during standard of care genetic counseling.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
64
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Health System
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Either a) pathologically confirmed diagnosis of high-grade epithelial ovarian, fallopian or peritoneal cancer via biopsy or surgical pathology or b) cytologic diagnosis consistent with high-grade epithelial ovarian cancer.
- Presenting to Duke gynecologic oncology clinic or collaborating institution for first outpatient visit following pathologic or cytologic diagnosis. If logistic constraints prevent the patient from being enrolled at her initial visit, she will be eligible for enrollment up to initiation of her fifth cycle of chemotherapy.
Exclusion Criteria:
- Known family or personal history of an inherited cancer susceptibility mutation
- Previously received genetic counseling or testing for an inherited cancer susceptibility mutation
- Insurance provided by an insurance company that requires face-to-face genetic consultation prior to testing
- Unable to read or speak English as study design includes video assisted educational materials in English
- Blind or deaf as study design includes video assisted educational materials in English
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Tradition Counseling Group (TG)
After completion of baseline surveys, the TG subjects will be referred to a formal pre-test consultation with a genetic counselor.
TG subjects will complete an electronic family history questionnaire (FHQ) within one week of the primary visit.
A member of the genetics team will curate the results by contacting the subject to review errors and clarify any ambiguities in the pedigree.
The TG subjects will then meet with the genetic counselor.
After counseling, participants will be given the option to undergo a multi-gene panel genetic test.
Those who agree to testing will also complete the standard genetic testing consent form.
As per standard practice, patients will also be asked to provide consent for somatic tumor testing of surgical (non-cytologic) specimen.
Subjects will complete a post-education distress and anxiety survey (IES) either via an email link to a confidential REDCap survey link 1-2 weeks after formal consultation.
|
The TG subjects will then meet with the genetic counselor at the previously scheduled appointment time.
During this visit, they will receive approximately thirty to sixty minutes of counseling regarding genetic testing and potential results.
The discussion is based on the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines of informed consent for genetic testing.
After counseling, participants will be given the option to undergo a multi-gene panel genetic test either via saliva or blood sample.
Those who agree to testing will also complete the standard genetic testing consent form.
As per standard practice of the clinical genetic service at DCI, patients will also be asked to provide consent for somatic tumor testing of surgical specimen (non-cytologic).
|
EXPERIMENTAL: Streamlined Group (SG)
After completion of the baseline surveys, the SG subjects will watch an approximately eight minute long genetics education video.
All subjects will then have the option to "opt out" and receive formal genetic counseling prior to making a decision about testing.
If the subject elects to undergo genetic testing, she will fill out the standard genetic testing consent form.
As per standard practice of the clinical genetic service at Duke Cancer Institute (DCI), patients will also be asked to provide consent for somatic tumor testing of surgical (non-cytologic) specimen.
SG subjects will complete an FHQ within one week of the primary visit.
A member of the genetics team will curate the results by contacting the subject to review common errors and clarify any ambiguities in the pedigree.
Subjects will complete a post-education distress and anxiety survey (IES) via either an email link to a confidential REDCap survey link or over the phone 1-2 weeks after education.
|
After completion of the baseline surveys, the SG subjects will watch an approximately eight minute long genetics education video.
This video will be made with the assistance of Duke University genetic counselors and gynecologic oncology providers.
It will consist of a discussion of genes and mutations, the recommendation of universal testing for high grade epithelial ovarian cancer, a review of genes associated with ovarian cancer predisposition, the possibility of uncertain results including variants of undetermined significance, the potential for undetected mutations in known or unknown cancer susceptibility genes, the potential impact on personal treatment and on family members, the possibility of genetic discrimination and the legal protection of genetic information.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Demographic Information
Time Frame: Baseline
|
Number of participants with children
|
Baseline
|
Numeracy assessment
Time Frame: Baseline
|
Numeracy as assessed by the Newest Vital Sign survey
|
Baseline
|
Electronic Family History
Time Frame: Completed at least 1 week prior to genetic sample being taken
|
Family cancer history up to past 3 generations
|
Completed at least 1 week prior to genetic sample being taken
|
Change in anxiety and depression as measured by the IES Scale
Time Frame: Baseline, approximately 7 days post-education, and approximately 7 days post-results disclosure
|
The Impact of Events Scale (IES) has been used widely as a means of measuring patient distress (particularly intrusive thoughts or avoidance) over a defined incident.
This evaluation will be used to identify trends in anxiety or depression in both arms throughout the education and testing process.
In this trial, the "incident" will be described as "the risk of my cancer being hereditary."
|
Baseline, approximately 7 days post-education, and approximately 7 days post-results disclosure
|
Distress as measured by MICRA
Time Frame: Approximately 7 days post-results disclosure
|
The multidimensional impact of cancer risk assessment questionnaire (MICRA) is a 25-question validated tool that measures the impact of result disclosure in patients, particularly markers of distress
|
Approximately 7 days post-results disclosure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Rebecca Previs, MD, MS, Duke Health
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
August 8, 2019
Primary Completion (ACTUAL)
July 31, 2021
Study Completion (ACTUAL)
July 31, 2021
Study Registration Dates
First Submitted
August 26, 2020
First Submitted That Met QC Criteria
August 31, 2020
First Posted (ACTUAL)
September 3, 2020
Study Record Updates
Last Update Posted (ACTUAL)
August 26, 2021
Last Update Submitted That Met QC Criteria
August 25, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Fallopian Tube Diseases
- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Carcinoma, Ovarian Epithelial
Other Study ID Numbers
- PRO00100538
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fallopian Tube Cancer
-
OncoMed Pharmaceuticals, Inc.CompletedCancer Ovaries | Cancer Peritoneal | Cancer, Fallopian TubeUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedStage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian... and other conditionsUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...Istituto Di Ricerche Farmacologiche Mario Negri; Foundation MedicineRecruitingAdvanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube CancerItaly
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Active, not recruitingStage I Ovarian Cancer AJCC v6 and v7 | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC v6 and v7 | Stage II Ovarian Cancer AJCC v6 and v7 | Stage IIA Fallopian Tube Cancer AJCC v6 and v7 | Stage IIB Fallopian... and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterGenentech, Inc.CompletedOvarian Cancer | Peritoneal Cancer | Fallopian Tubes CancerUnited States
-
Genentech, Inc.CompletedOvarian Cancer | Fallopian Tube Cancer | Peritoneal CancerUnited States
-
Precision TherapeuticsCompletedOvarian Cancer | Fallopian Tube Cancer | Peritoneal CancerUnited States
-
Centre Jean PerrinCompletedOvarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity CancerFrance
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer | Stage IIA Fallopian Tube Cancer | Stage IIB Fallopian Tube Cancer | Stage IIC Fallopian Tube Cancer | Stage... and other conditions
Clinical Trials on Traditional Education
-
Keller Army Community HospitalCompletedChronic Low Back Pain | Post-traumatic StressUnited States
-
Chulabhorn HospitalCompletedSurgery | Educational Problems
-
Universiti Putra MalaysiaRecruitingPerformance | Physical FitnessChina
-
Riphah International UniversityCompleted
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Kutahya Health Sciences UniversityCompletedQuality of Life | Pain | Chronic Low Back PainTurkey
-
Saglik Bilimleri UniversitesiCompletedDiabetes | Educational ProblemsTurkey
-
National Taipei University of Nursing and Health...Mackay Memorial HospitalCompletedCardiac Implantable Electronic DeviceTaiwan
-
National Taiwan University HospitalRecruiting
-
Hospital Nossa Senhora da ConceicaoFederal University of Rio Grande do SulUnknownDental Caries | Early Childhood Caries